{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T11:24:55Z","timestamp":1767007495996},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2004,4,13]],"date-time":"2004-04-13T00:00:00Z","timestamp":1081814400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1038\/sj.bjc.6601796","type":"journal-article","created":{"date-parts":[[2004,5,18]],"date-time":"2004-05-18T16:08:34Z","timestamp":1084896514000},"page":"1715-1719","source":"Crossref","is-referenced-by-count":31,"title":["Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil\/leucovorin for locally advanced or metastatic carcinoma of the biliary tract"],"prefix":"10.1038","volume":"90","author":[{"given":"C","family":"Hsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y-C","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C-H","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K-H","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y-S","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C-H","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H-T","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C-C","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J-S","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C-Y","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A-L","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,4,13]]},"reference":[{"issue":"Suppl 6","key":"BF6601796_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0959-8049(01)80552-9","volume":"37","author":"T Andre","year":"2001","unstructured":"Andre T, Louvet C, Amu P, Selle F, Tournigand C, Garcia ML, Avenin D, Maindraults F, Provent S, de Gramont A (2001) A phase II study of gemcitabine and oxaliplatln (gemox) in advanced blliary adenocarcinoma (ABA). Preliminary results. Eur J Cancer 37(Suppl 6): 19 (abstrct A60)","journal-title":"Eur J Cancer"},{"key":"BF6601796_CR2","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1200\/JCO.1991.9.4.625","volume":"9","author":"B Ardalan","year":"1991","unstructured":"Ardalan B, Chua L, Tian EM, Reddy R, Sridhar K, Benedetto P, Richman S, Legaspi A, Waldman S, Morrell L (1991) A phase II study of weekly 24-h infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 9: 625\u2013630","journal-title":"J Clin Oncol"},{"key":"BF6601796_CR3","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris","year":"1997","unstructured":"Burris HA, Moore MJ, Anderson J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvement is survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403\u20132413","journal-title":"J Clin Oncol"},{"key":"BF6601796_CR4","first-page":"2333","volume":"20","author":"S Carraro","year":"2001","unstructured":"Carraro S, Servienti PJ, Bruno MF, Odena M, Roca E, Jovtis S, Felci N, Araujo C (2001) Gemcitabine and cisplatin in locally advanced or metastatic gallbladder and bile duct adenocarcinomas. Proc Am Soc Clin Oncol 20: 2333 (abstract)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6601796_CR5","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S0959-8049(97)00364-X","volume":"34","author":"A de Gramont","year":"1998","unstructured":"de Gramont A, Louvet C, Andre T, Tournigand C, Krulik M (1998) A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). Eur J Cancer 34: 619\u2013626","journal-title":"Eur J Cancer"},{"key":"BF6601796_CR6","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1056\/NEJM199910283411807","volume":"341","author":"PC de Groen","year":"1999","unstructured":"de Groen PC, Larusso NF, Gunderson LL, Gunderson LL, Nagorney DM (1999) Biliary tract cancers. N Engl J Med 341: 1368\u20131378","journal-title":"N Engl J Med"},{"key":"BF6601796_CR7","first-page":"622","volume":"20","author":"DC Doval","year":"2001","unstructured":"Doval DC, Sekhon JS, Fuloria J, Gupta SK, Vaid AK, Gupta S, Shukla VK (2001) Gemcitabine and cisplatin in chemotherapy-naive, unresectable gallbladder cancer: a large multicenter, phase II study. Proc Am Soc Clin Oncol 20: 622 (abstract)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6601796_CR8","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/1097-0142(19840915)54:6<965::AID-CNCR2820540603>3.0.CO;2-X","volume":"54","author":"G Falkson","year":"1984","unstructured":"Falkson G, Macintyre JM, Moertel CG (1984) Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 54: 965\u2013969","journal-title":"Cancer"},{"key":"BF6601796_CR9","volume-title":"American Joint Committee on Cancer Staging Manual","author":"ID Fleming","year":"1997","unstructured":"Fleming ID (ed) (1997) American Joint Committee on Cancer Staging Manual, 5th edn, Philadelphia: Lippincott, Willaims & Wilkins"},{"key":"BF6601796_CR10","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1200\/JCO.1997.15.1.310","volume":"15","author":"FV Fossella","year":"1997","unstructured":"Fossella FV, Lippman SM, Shin DM, Tarassoff P, Calayag-Jung M, Perez-Soler R, Lee JS, Murphy WK, Glisson B, Rivera E, Hong WK (1997) Maximum tolerated dose defined for single agent gemcitabine: a phase I dose-escalation study in chemotherapy-na\u00efve patients with advanced non-small-cell lung cancer. J Clin Oncol 15: 310\u2013316","journal-title":"J Clin Oncol"},{"key":"BF6601796_CR11","doi-asserted-by":"publisher","first-page":"4088","DOI":"10.1200\/JCO.2001.19.20.4089","volume":"19","author":"V Gebbia","year":"2001","unstructured":"Gebbia V, Giuliani F, Maiello E, Colucci G, Verderame F, Borsellino N, Mauceri G, Caruso M, Tirrito ML, Valdesi M (2001) Treatment of inoperable and\/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol 19: 4088\u20134091, (correspondence)","journal-title":"J Clin Oncol"},{"key":"BF6601796_CR12","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1200\/JCO.1984.2.11.1245","volume":"2","author":"JH Harvey","year":"1984","unstructured":"Harvey JH, Smith FP, Sehien PS (1984) 5-Fluorouracil, mitomycin and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol 2: 1245\u20131248","journal-title":"J Clin Oncol"},{"key":"BF6601796_CR13","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S0959-8049(97)10166-6","volume":"34","author":"M Hejna","year":"1998","unstructured":"Hejna M, Pruckmayer M, Raderer M (1998) The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. Eur J Cancer 34: 977\u2013986","journal-title":"Eur J Cancer"},{"key":"BF6601796_CR14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1159\/000227702","volume":"54","author":"CH Hsu","year":"1997","unstructured":"Hsu CH, Yeh KH, Chen LT, Liu JM, Jan CM, Lin JT, Chen YC, Cheng AL (1997) Weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers: an effective and low-toxic regimen for patients with poor general condition. Oncology 54: 275\u2013280","journal-title":"Oncology"},{"key":"BF6601796_CR15","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1200\/JCO.1994.12.8.1527","volume":"12","author":"SB Kaye","year":"1994","unstructured":"Kaye SB (1994) Gemcitabine: current status of phase I and phase II trails. J Clin Oncol 12: 1527\u20131531","journal-title":"J Clin Oncol"},{"key":"BF6601796_CR16","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1200\/JCO.1998.16.2.418","volume":"16","author":"CH Koehne","year":"1998","unstructured":"Koehne CH, Schoffski P, Wilke H, Kaufer C, Andreesen R, Ohl U, Klaasen U, Westerhausen M, Hiddemann W, Schott G, Harstick A, Bade J, Horster A, Schubert U, Hecker H, Dorken B, Schmoll HJ (1998) Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-h infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol 16: 418\u2013426","journal-title":"J Clin Oncol"},{"key":"BF6601796_CR17","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1200\/JCO.2003.11.122","volume":"21","author":"CH Koehne","year":"2003","unstructured":"Koehne CH, Wils J, Lorenz M, Schoeffski P, Voigtmann R, Bokemeyer C, Lutz M, Kleeberg U, Ridwelski K, Souchon R, El-Serafi M, Weiss U, Burkhard O, Rueckle H, Lichinitser M, Langenbuch T, Scheithauer W, Baron B, Couvreur ML, Schmoll HJ (2003) Randomized phase III study of high-dose fluorouracil given as a weekly 24-h infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestival Group study 40952. J Clin Oncol 21: 3721\u20133728","journal-title":"J Clin Oncol"},{"key":"BF6601796_CR18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207\u2013214","journal-title":"Cancer"},{"key":"BF6601796_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/BF01658494","volume":"12","author":"RA Oberfield","year":"1988","unstructured":"Oberfield RA, Rossi RL (1988) The role of chemotherapy in the treatment of bile duct cancer. World J Surg 12: 105\u2013108","journal-title":"World J Surg"},{"key":"BF6601796_CR20","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1200\/JCO.2001.19.9.2413","volume":"19","author":"PJ O'Dwyer","year":"2001","unstructured":"O'Dwyer PJ, Manola J, Valone FH, Ryan LM, Hines JD, Wadler S, Haller DG, Arbuck SG, Weiner LM, Mayer RJ, Benson AB (2001) Fluorouracil modulation in colorectal cancer: lack of improvement with N-phosphonoacetyl-l-aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-h infusion schedule \u2013 an Eastern Cooperative Oncology Group\/Cancer and Leukemia Group B study. J Clin Oncol 19: 2413\u20132421","journal-title":"J Clin Oncol"},{"key":"BF6601796_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1159\/000227396","volume":"51","author":"S Okada","year":"1994","unstructured":"Okada S, Ishii H, Nose H, Yoshimori M, Okusaka T, Aoki K, Iwasaki M, Furuse J, Yoshino M (1994) A phase II study of cisplatin in patients with biliary tract carcinoma. Oncology 51: 515\u2013517","journal-title":"Oncology"},{"key":"BF6601796_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1159\/000011961","volume":"56","author":"M Raderer","year":"1999","unstructured":"Raderer M, Hejna M.H.L, Valencak J.B, Kornek GV, Weinlander GS, Bareck E, Lenauer J, Brodowicz T, Lang F, Scheithauer W (1999) Two consecutive phase II studies of 5-fluorouracil\/leucovorin\/mitomycin-C and of gemcitabine in patients with advanced biliary cancer. Oncology 56: 177\u2013180","journal-title":"Oncology"},{"key":"BF6601796_CR23","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1200\/JCO.2003.05.987","volume":"21","author":"LB Saltz","year":"2003","unstructured":"Saltz LB (2003) Another study of how to give fluorouracil? J Clin Oncol 21: 3711\u20133712 (editorial)","journal-title":"J Clin Oncol"},{"issue":"Suppl 20","key":"BF6601796_CR24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1053\/sonc.2002.37380","volume":"29","author":"W Scheithauer","year":"2002","unstructured":"Scheithauer W (2002) Review of gemcitabine in biliary tract carcinoma. Semin Oncol 29(Suppl 20): 40\u201345","journal-title":"Semin Oncol"},{"key":"BF6601796_CR25","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1200\/JCO.1991.9.1.191","volume":"9","author":"JJ Shuster","year":"1991","unstructured":"Shuster JJ (1991) Median follow-up in clinical trials. J Clin Oncol 9: 191\u2013192 (letter)","journal-title":"J Clin Oncol"},{"key":"BF6601796_CR26","first-page":"521","volume-title":"Cancer: Principle and Practice of Oncology","author":"R Simon","year":"2001","unstructured":"Simon R (2001) Design and conduct of clinical trials. In Cancer: Principle and Practice of Oncology, DeVita VT, Hellman S, Rosenberg SA (eds) pp 521\u2013538. Philadelphia: Lippincott, Williams & Wilkins"},{"key":"BF6601796_CR27","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1093\/oxfordjournals.annonc.a058597","volume":"4","author":"BG Taal","year":"1993","unstructured":"Taal BG, Audisio RA, Bleiberg H, Blijham GH, Neijt JP, Veenhof CH, Duez N, Sahmoud T (1993) Phase II trial of mitomycin C in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cooperative Group Study. Ann Oncol 4: 607\u2013609","journal-title":"Ann Oncol"},{"key":"BF6601796_CR28","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1200\/JCO.2003.09.140","volume":"21","author":"M Tempero","year":"2003","unstructured":"Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21: 3402\u20133408","journal-title":"J Clin Oncol"},{"key":"BF6601796_CR29","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1023\/A:1008487932384","volume":"9","author":"N Touroutoglou","year":"1998","unstructured":"Touroutoglou N, Gravel D, Raber MN, Plunkett W, Abbruzzese JL (1998) Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol 9: 1003\u20131008","journal-title":"Ann Oncol"},{"key":"BF6601796_CR30","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/bjc.1997.79","volume":"75","author":"KH Yeh","year":"1997","unstructured":"Yeh KH, Cheng AL (1997) High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy. Br J Cancer 75: 464\u2013465","journal-title":"Br J Cancer"},{"key":"BF6601796_CR31","first-page":"3867","volume":"17","author":"KH Yeh","year":"1997","unstructured":"Yeh KH, Cheng AL, Lin MT, Hong RL, Hsu CH, Lin JF, Chang KJ, Lee PH, Chen YC (1997) A phase II study of weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers. Anticancer Res 17: 3867\u20133872","journal-title":"Anticancer Res"},{"key":"BF6601796_CR32","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1034\/j.1600-0773.2000.d01-22.x","volume":"86","author":"KH Yeh","year":"2000","unstructured":"Yeh KH, Yeh SH, Chang YS, Cheng AL (2000a) Minimal toxicity to myeloid progenitor cells of weekly 24-h infusion of 5-fluorouracil: direct evidence from colony forming unti-granulocyte and monocyte (CFU-GM) clonogenic assay. Pharmacol Toxicol 86: 122\u2013124","journal-title":"Pharmacol Toxicol"},{"key":"BF6601796_CR33","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1054\/bjoc.2000.1456","volume":"83","author":"KH Yeh","year":"2000","unstructured":"Yeh KH, Yeh SH, Hsu CH, Wang TM, Ma IF, Cheng AL (2000b) Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil. Br J Cancer 83: 1510\u20131515","journal-title":"Br J Cancer"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6601796.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6601796","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6601796.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:07:00Z","timestamp":1684411620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6601796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4,13]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["BF6601796"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6601796","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4,13]]}}}